MDxHealth SA (NASDAQ:MDXH) Sees Large Decline in Short Interest

MDxHealth SA (NASDAQ:MDXH) was the target of a significant drop in short interest in April. As of April 15th, there was short interest totaling 19,213 shares, a drop of 73.9% from the March 31st total of 73,632 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 262,452 shares, the days-to-cover ratio is currently 0.1 days.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of MDxHealth in a research report on Friday, March 27th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, MDxHealth currently has an average rating of “Moderate Buy” and an average target price of $7.75.

MDxHealth Price Performance

MDxHealth stock traded down $0.09 during mid-day trading on Friday, hitting $2.08. 105,362 shares of the company’s stock traded hands, compared to its average volume of 203,563. MDxHealth has a fifty-two week low of $1.67 and a fifty-two week high of $5.33. The stock has a market cap of $102.95 million, a price-to-earnings ratio of -3.10 and a beta of 1.73. The firm has a 50 day simple moving average of $2.86 and a two-hundred day simple moving average of $3.45.

MDxHealth (NASDAQ:MDXH) last announced its quarterly earnings results on Friday, February 27th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.04). The company had revenue of $29.55 million during the quarter, compared to analyst estimates of $26.05 million. MDxHealth had a negative net margin of 31.07% and a negative return on equity of 1,078.01%. On average, research analysts anticipate that MDxHealth will post -0.41 earnings per share for the current fiscal year.

Institutional Trading of MDxHealth

Hedge funds and other institutional investors have recently bought and sold shares of the business. Perkins Capital Management Inc. grew its position in shares of MDxHealth by 7.1% during the 1st quarter. Perkins Capital Management Inc. now owns 1,476,441 shares of the company’s stock worth $3,396,000 after purchasing an additional 97,500 shares in the last quarter. Kennedy Capital Management LLC bought a new stake in shares of MDxHealth in the third quarter valued at approximately $1,826,000. FreeGulliver LLC boosted its stake in shares of MDxHealth by 25.7% in the fourth quarter. FreeGulliver LLC now owns 317,894 shares of the company’s stock valued at $1,135,000 after buying an additional 65,000 shares during the period. Mink Brook Asset Management LLC grew its position in MDxHealth by 64.9% during the fourth quarter. Mink Brook Asset Management LLC now owns 263,420 shares of the company’s stock worth $940,000 after buying an additional 103,686 shares in the last quarter. Finally, Renaissance Technologies LLC increased its stake in MDxHealth by 23.3% during the 4th quarter. Renaissance Technologies LLC now owns 250,100 shares of the company’s stock worth $893,000 after acquiring an additional 47,300 shares during the period.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.